Epidemiology. Impact of metabolic syndrome in the public health in Spain;Epidemiología. Impacto del síndrome metábolico en la salud pública en España

Medicina Clinica Monografias

Volumn 7, Issue 4, 2006, Pages 8-12

  Pérez Jiménez, Francisco ^a   Mora Navarro, Gustavo ^b,c   Díez Espino, Javier ^c,d  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Centro de Salud Federica Montseny   (Spain)

^c Grupo de Trabajo de Cuidados Paliativos semFYC   (Spain)

^d Centro de Salud Tafalla   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; CAUCASIAN; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HISPANIC; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORTALITY; NEGRO; OBESITY; PREVALENCE; PUBLIC HEALTH SERVICE; REVIEW; SEX RATIO; SPAIN;

EID: 33750474031     PISSN: 15771512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The Metabolic Syndrome. Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-36.
2. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26:575-81.
3. Hu G, Qiao A, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med. 2004;164:1066-76.
4. Martínez de Morentin BE, Rodríguez MC, Martínez JA. Síndrome metabólico, resistencia a la insulina y metabolismo tisular. Endocrinol Nutr. 2003;50:324-33.
5. Álvarez EE, Ribas L, Serra LI. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. Med Clin. 2003;120:172-4.
6. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilento V. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-16.
7. García S, Stiefel P, Miranda ML, Vallejo I, Pamies E, Muñiz O, et al. Efectividad de la glucosa y componentes del síndrome metabólico en pacientes con hipertensión arterial esencial de diagnóstico reciente. Med Clin. 2002;119:527-30.
8. Vázquez A, Vázquez A, Calderín O, Buchaca. F, Cruz M, Jiménez R, et al. Síndrome metabólico. Nefrología. 2003;23:423-31.
9. Hernández A, Riera C, Solá E, Oliver MJ, Martínez ML, Morillas C, et al. Prevalencia del síndrome metabólico entre pacientes con cardiopatía isquémica. Med Clin. 2003;121:204-8.
10. Gimeno J, Lou L, Molinero E, Boned B, Portilla D. Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2. Rev Esp Cardiol. 2004;57:507-13.
11. Meigs JB, Williams K, Sullivan LM, Hunt KJ, Haffner SM, Stern MP, et al. Using Metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care. 2004;27:1417-26.
12. Banegas JR, López-Garcia E, Gutiérrez-Fisac JL, Guallar-Castillon P, Rodríguez-Artalejo F. A simple estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr. 2003;57:201-8.
13. Kearny K, Kearney JM, Gibney MJ. Method used to conduct the survey on consumer attitudes to food, nutrition and health on nationally representative samples of adults from each member state of the European Union. Eur J Clin Ntr. 1997;51(Supl 2):S3-7.
14. Banegas JR, Rodríguez-Artalejo F, Graciani A, Villar F, Herruzo R. Mortality attributable to cardiovascular risk factors in Spain. Eur J Clin Nutr. 2003;57(Supl 1):S18-21.